Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A new era for schizophrenia drug development – Lessons for the future
Kiri Granger, Michael Sand, Sheryl Caswell, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 7, pp. 103603-103603
Open Access | Times Cited: 14

Showing 14 citing articles:

QSPR Analysis of Drugs for Treatment of Schizophrenia Using Topological Indices
Xiujun Zhang, Muhammad Jawwad Saif, Nazeran Idrees, et al.
ACS Omega (2023) Vol. 8, Iss. 44, pp. 41417-41426
Open Access | Times Cited: 18
Novel Compounds in the Treatment of Schizophrenia—A Selective Review
Eva-Maria Tsapakis, Kalliopi Diakaki, Apostolos Miliaras, et al.
Brain Sciences (2023) Vol. 13, Iss. 8, pp. 1193-1193
Open Access | Times Cited: 17
The Long and Winding Road of Schizophrenia Drug Development
Ben Huang
Journal of Pharmacology and Experimental Therapeutics (2025) Vol. 392, Iss. 3, pp. 103391-103391
Closed Access
Quetiapine Fumarate-Loaded Mixed Micelles in Nasal In-Situ Gels: Enhancing Efficacy for Schizophrenia Management
Prashant Keshavrao Puranik, Yogesh Dhanraj Chainani, Ujban Hussain
Next research. (2025), pp. 100234-100234
Closed Access
The trace amine-associated receptor 1 agonists – non-dopaminergic antipsychotics or covert modulators of D2 receptors?
Gavin P. Reynolds
Journal of Psychopharmacology (2024) Vol. 38, Iss. 6, pp. 503-506
Open Access | Times Cited: 2
Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunities
Na Ye, Qi Wang, Yue Li, et al.
Medicinal Research Reviews (2024)
Closed Access | Times Cited: 2
IUPHAR Review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia.
Brian Dean
Pharmacological Research (2024) Vol. 210, pp. 107510-107510
Open Access | Times Cited: 2
Brexpiprazole in patients with schizophrenia with or without substance use disorder: an observational study
Ginevra Lombardozzi, Giada Trovini, Emanuela Amici, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 5
Novel Compounds for the Treatment of Schizophrenia – A Narrative Review
Kalliopi Diakaki, Apostolos Miliaras, Eva-Maria Tsapakis, et al.
(2023)
Open Access | Times Cited: 2
Enhancing drug discovery in schizophrenia: a deep learning approach for accurate drug-target interaction prediction – DrugSchizoNet
S. J., P. Durgadevi, P. Ezhumalai
Computer Methods in Biomechanics & Biomedical Engineering (2024), pp. 1-18
Closed Access
Polypharmacy in Psychiatry: An In-depth Examination of Drug-drug Interactions and Treatment Challenges
Devank Shekho, Ritika Mishra, Raj Kamal, et al.
Current Pharmaceutical Design (2024) Vol. 30, Iss. 21, pp. 1641-1649
Closed Access
The antipsychotic potential of Salix Mucronata on ketamine-induced rats
Ntombifuthi P. Ngubane, Musa V. Mabandla, Brenda Z. De Gama
IBRO Neuroscience Reports (2024) Vol. 17, pp. 96-107
Open Access
Neuropsychiatric drug development: Perspectives on the current landscape, opportunities and potential future directions
Simon Loïodice, Fulvio D’Acquisto, Pim Drinkenburg, et al.
Drug Discovery Today (2024) Vol. 30, Iss. 1, pp. 104255-104255
Open Access
Exploring Cognitive Deficits and Neuromodulation in Schizophrenia: A Narrative Review
C. L. Hung, Ko-Huan Lin, Hsin‐An Chang
Medicina (2024) Vol. 60, Iss. 12, pp. 2060-2060
Open Access
Page 1

Scroll to top